Vogenx VOGX

R&D: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

SG&A: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

Net income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.

EPS, diluted: Q1 FY25 and Q1 FY26: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY25 and Q1 FY26: share-days: the 6-month average less the second quarter's.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Companies in Drug Manufacturers - General nearest Vogenx's size, closest first.

Company	Market cap	PE	Its 10y median PE	Fwd PE	P/S	Revenue growth	Net margin
VOGXVogenx	$259.2M	n/m	n/a		n/m	n/m	n/m
NATRNatures Sunshine Products	$213.8M	12.0×	20.6×		0.4×	+7%	3.7%
ARVNArvinas	$477.3M	45.6×	52.3×		1.5×	−15%	2.9%
PBYIPuma Biotechnology	$568.9M	21.2×	12.3×		2.5×	−3%	11.6%
IRWDIronwood Pharmaceuticals	$571.7M	4.5×	14.9×		1.5×	+26%	33.4%
ZVRAZevra Therapeutics	$582.6M	10.5×	12.3×		4.3×	+119%	42.8%
CRMDCorMedix	$611.9M	3.7×	4.0×		1.3×	+281%	40.5%
COLLCollegium Pharmaceutical	$747.5M	18.5×	19.1×		0.9×	+14%	5.9%
ABUSArbutus Biopharma	$831M	5.4×	5.6×		4.6×	n/m	84.2%
LFVNLifevantage	$73.4M	14.7×	19.6×		0.4×	−20%	2.8%
SPROSpero Therapeutics	$64.6M	10.1×	9.5×		1.4×	−3%	15.7%
Peer median	$570.3M	11.3×	13.6×		1.4×	+7%	13.6%

Each number over time

• EPS
• Shares outstanding

Its groups

• Drug Manufacturers - General
• Healthcare

Industry

Drug Manufacturers - General

Sector

Healthcare